BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50
Express News | Outlook Therapeutics® Announces UK Mhra Marketing Authorization of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects
Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases
Express News | Outlook Therapeutics Inc - Strategic Partnership With Cencora (Formerly Amerisourcebergen) to Support Planned Commercial Launches of Lytenava in EU
Express News | Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
Express News | Outlook Therapeutics Inc - Advancing Toward Commercial Launch of Lytenava™ (Bevacizumab Gamma) in EU Expected in Calendar Q1 2025
Express News | Outlook Therapeutics® Receives European Commission Marketing Authorization for Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
Express News | HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target
Buy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial Position
Q2 2024 Outlook Therapeutics Inc Earnings Call
Earnings Call Summary | Outlook Therapeutics(OTLK.US) Q2 2024 Earnings Conference
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
Express News | Outlook Therapeutics Inc - Qtrly Shr Loss $8.01
Outlook Therapeutics | 10-Q: Quarterly report
Express News | Outlook Therapeutics Q2 2024 Adj EPS $(1.55) Misses $(0.85) Estimate